Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

@article{Herbrecht2002VoriconazoleVA,
  title={Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.},
  author={Raoul Herbrecht and David William Denning and Thomas F. Patterson and John E. Bennett and Reginald E. Greene and J. Oestmann and Winfried V Kern and Kieren a. Marr and Patricia Ribaud and Olivier Lortholary and Richard Sylvester and Robert H. Rubin and John R Wingard and Paul Stark and Christine Durand and Denis Caillot and Eckhard Thiel and Pranatharthi Chandrasekar and Michael R Hodges and Haran T. Schlamm and Peter F. Troke and Ben E. de Pauw},
  journal={The New England journal of medicine},
  year={2002},
  volume={347 6},
  pages={408-15}
}
BACKGROUND Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis. METHODS In this randomized, unblinded trial, patients received either intravenous voriconazole (two doses of 6 mg per kilogram of body weight on day 1, then 4 mg per kilogram twice daily for at least seven days) followed by 200 mg orally twice daily or intravenous amphotericin… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 75 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Similar Papers

Loading similar papers…